Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 11 (2)

Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes Through Complex Formulation


Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes Through Complex Formulation

Callum J Cooper et al. Pharmaceuticals (Basel).


The resurgence of research into phage biology and therapy is, in part, due to the increasing need for novel agents to treat multidrug-resistant infections. Despite a long clinical history in Eastern Europe and initial success within the food industry, commercialized phage products have yet to enter other sectors. This relative lack of success is, in part, due to the inherent biological limitations of whole phages. These include (but are not limited to) reaching target sites at sufficiently high concentrations to establish an infection which produces enough progeny phages to reduce the bacterial population in a clinically meaningful manner and the limited host range of some phages. Conversely, parallels can be drawn between antimicrobial enzymes derived from phages and conventional antibiotics. In the current article the biological limitations of whole phage-based therapeutics and their derived antimicrobial enzymes will be discussed. In addition, the ability of more complex formulations to address these issues, in the context of medical and non-medical applications, will also be included.

Keywords: bacteriophage; combination therapy; formulation; pharmacology; product development; synergy.

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by 4 PubMed Central articles


    1. Van Boeckel T.P., Gandra S., Ashok A., Caudron Q., Grenfell B.T., Levin S.A., Laxminarayan R. Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. Lancet Infect. Dis. 2014;14:742–750. doi: 10.1016/S1473-3099(14)70780-7. - DOI - PubMed
    1. Van Boeckel T.P., Brower C., Gilbert M., Grenfell B.T., Levin S.A., Robinson T.P., Teillant A., Laxminarayan R. Global trends in antimicrobial use in food animals. Proc. Natl. Acad. Sci. USA. 2015;112:5649–5654. doi: 10.1073/pnas.1503141112. - DOI - PMC - PubMed
    1. Webber M.A., Whitehead R.N., Mount M., Loman N.J., Pallen M.J., Piddock L.J.V. Parallel evolutionary pathways to antibiotic resistance selected by biocide exposure. J. Antimicrob. Chemother. 2015;70:2241–2248. doi: 10.1093/jac/dkv109. - DOI - PMC - PubMed
    1. Soumet C., Méheust D., Pissavin C., Le Grandois P., Frémaux B., Feurer C., Le Roux A., Denis M., Maris P. Reduced susceptibilities to biocides and resistance to antibiotics in food-associated bacteria following exposure to quaternary ammonium compounds. J. Appl. Microbiol. 2016;121:1275–1281. doi: 10.1111/jam.13247. - DOI - PubMed
    1. Ng K.M., Ferreyra J.A., Higginbottom S.K., Lynch J.B., Kashyap P.C., Gopinath S., Naidu N., Choudhury B., Weimer B.C., Monack D.M., et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature. 2013;502:96–99. doi: 10.1038/nature12503. - DOI - PMC - PubMed